摘要
目的:探讨微生物制剂美常安(枯草杆菌二联活菌肠溶胶囊)与胃肠动力药莫沙必利分散片联合治疗便秘型肠易激综合征的临床疗效与安全性。方法:采用随机对照研究,将98例便秘型肠易激综合征患者分为两组,A组为治疗组,49例,予枯草杆菌二联活菌肠溶胶囊500mg/次,3次/d,口服,同时莫沙必利分散片5mg/次,3次/d,疗程为8周。B组为对照组,49例,给予枯草杆菌二联活菌肠溶胶囊500mg/次,3次/d,口服,谷维素片20mg/次,3次/d,口服。治疗8周,观察治疗前后排便次数、大便性状、排便困难症状改善变化。结果:治疗组显效14例,有效28例,总有效率85.71%,明显高于对照组61.22%,比较差异有统计学意义(P<0.05),且并没有发现明显不良反应。结论:枯草杆菌二联活菌肠溶胶囊联合莫沙必利分散片治疗便秘型肠易激综合征能明显改善便秘症状,明显增加排便次数,并改善大便性状,缓解排便困难症状,安全性好。
Objective： To explore the effect of Medilac-s （ live combined bacillus subtilis and enterocoecus faeciumenteric-coated capsule ） combined with mosapride citrate tablets for the treatment of constipation-predominant irritable bowel syndrome （ IBS ） . Method： IBS patients were randomly divided into 2 groups, the treatment group received Medilac-s 500 mg 3 times and mosapride citrate tablets 5 mg 3 times daily for 8 weeks. The control group received oryzanol tablets 20 mg 3 times a clay for 8 weeks, Medilac-s 500 mg 3 times daily for 8 weeks. Result： The total efficiency rate of treatment group was 85.71%, and control group was 61.22% （ P〈0.05 ） . Conclusion： Medilac-s combined with mosapride citrate tablets has better effect in the treatment of constipation-predominant irritable bowel syndrome.
出处
《中国医学创新》
CAS
2013年第15期59-60,共2页
Medical Innovation of China
